1. In Vivo
  2. >>Archive

Teva and Ivax Bet on French Generics

Although generics still account for a paltry percentage of prescription drug usage in France, Ivax and Teva reckon the market is set to grow. Last April Ivax acquired all the products within Merck Sharpe & Dohme; just days later, Teva bought Bayer's French generics business. Teva and Ivax clearly hope that France-the world's fourth largest drug market-will follow its neighbors Germany and the UK, where generics represent a far greater proportion of the total pharmaceutical market.

Although generics still account for a paltry percentage of prescription drug usage in France, Ivax Corp. and Teva Pharmaceutical Industries Ltd. reckon the market is set to grow. Last April Ivax acquired all the products within Merck & Co. Inc. 's French subsidiary Laboratoire Merck Sharpe & Dohme (MSD)-Chibret, and just days later, Teva bought Bayer Classics SA , Bayer AG 's French generics business, ranked third in France in 2001 [See Deal][See Deal].

Teva and Ivax hope France—the world's fourth largest drug market—will follow its neighbors Germany and the UK, where generics represent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.